Microdissected pancreatic cancer proteomes reveal tumor heterogeneity and therapeutic targets.

Pancreatic ductal adenocarcinoma (PDAC) is characterized by a relative paucity of cancer cells that are surrounded by an abundance of non-tumor cells and extracellular matrix, known as stroma. The interaction between stroma and cancer cells contributes to poor outcome, but how proteins from these individual compartments drive aggressive tumor behavior is not known. Here, we report the proteomic analysis of laser-capture microdissected (LCM) PDAC samples. We isolated stroma, tumor, and bulk samples from a cohort with long- and short-term survivors. Compartment-specific proteins were measured by mass spectrometry, yielding the largest PDAC proteome landscape to date. These analyses revealed that in bulk analysis, tumor-derived proteins were typically masked and that LCM was required to reveal biology and novel prognostic markers. We validated tumor CALB2 and stromal COL11A1 expression as compartment-specific prognostic markers. We identified and functionally addressed the contributions of the tumor cell receptor EPHA2 to tumor cell viability and motility, underscoring the value of compartment-specific protein analysis in PDAC.

[1]  M. J. van de Vijver,et al.  High‐grade mesenchymal pancreatic ductal adenocarcinoma drives stromal deactivation through CSF‐1 , 2020, EMBO reports.

[2]  S. Batra,et al.  Predicted Prognosis of Patients with Pancreatic Cancer by Machine Learning , 2020, Clinical Cancer Research.

[3]  M. J. van de Vijver,et al.  Unsupervised class discovery in pancreatic ductal adenocarcinoma reveals cell-intrinsic mesenchymal features and high concordance between existing classification systems , 2020, Scientific Reports.

[4]  Yulian Wu,et al.  FHL3 promotes pancreatic cancer invasion and metastasis through preventing the ubiquitination degradation of EMT associated transcription factors , 2020, Aging.

[5]  A. Jemal,et al.  Cancer statistics, 2020 , 2020, CA: a cancer journal for clinicians.

[6]  L. Wood,et al.  A unifying paradigm for transcriptional heterogeneity and squamous features in pancreatic ductal adenocarcinoma , 2020, Nature Cancer.

[7]  S. Carr,et al.  Proteomic analyses of ECM during pancreatic ductal adenocarcinoma progression reveal different contributions by tumor and stromal cells , 2019, Proceedings of the National Academy of Sciences.

[8]  J. Tobias,et al.  Tumor cell-intrinsic EPHA2 suppresses anti-tumor immunity by regulating PTGS2 (COX-2). , 2019, The Journal of clinical investigation.

[9]  S. Toyooka,et al.  Upregulation of mobility in pancreatic cancer cells by secreted S100A11 through activation of surrounding fibroblasts. , 2019, Oncology research.

[10]  Yun-Gui Yang,et al.  Single-cell RNA-seq highlights intra-tumoral heterogeneity and malignant progression in pancreatic ductal adenocarcinoma , 2019, Cell Research.

[11]  E. Giovannetti,et al.  Proteomic analysis of gemcitabine-resistant pancreatic cancer cells reveals that microtubule-associated protein 2 upregulation associates with taxane treatment , 2019, Therapeutic advances in medical oncology.

[12]  A. Califano,et al.  Experimental microdissection enables functional harmonisation of pancreatic cancer subtypes , 2019, Gut.

[13]  E. Giovannetti,et al.  Splicing modulation as novel therapeutic strategy against diffuse malignant peritoneal mesothelioma , 2018, EBioMedicine.

[14]  Thierry Lecomte,et al.  FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer , 2018, The New England journal of medicine.

[15]  Mathias Wilhelm,et al.  A deep proteome and transcriptome abundance atlas of 29 healthy human tissues , 2018, bioRxiv.

[16]  J. Iovanna,et al.  Speeding towards individualized treatment for pancreatic cancer by taking an alternative road. , 2017, Cancer letters.

[17]  Steven J. M. Jones,et al.  Integrated Genomic Characterization of Pancreatic Ductal Adenocarcinoma. , 2017, Cancer cell.

[18]  L. Vermeulen,et al.  Esophageal Adenocarcinoma Cells and Xenograft Tumors Exposed to Erb-b2 Receptor Tyrosine Kinase 2 and 3 Inhibitors Activate Transforming Growth Factor Beta Signaling, Which Induces Epithelial to Mesenchymal Transition. , 2017, Gastroenterology.

[19]  M. Büchler,et al.  Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial , 2017, The Lancet.

[20]  Hans Clevers,et al.  Distinct populations of inflammatory fibroblasts and myofibroblasts in pancreatic cancer , 2017, The Journal of experimental medicine.

[21]  Yonghong Shi,et al.  Prognostic value of GLUT-1 expression in pancreatic cancer: results from 538 patients , 2017, Oncotarget.

[22]  Yuan Yuan,et al.  Glypican-3 and KRT19 are markers associating with metastasis and poor prognosis of pancreatic ductal adenocarcinoma. , 2017, Cancer biomarkers : section A of Disease markers.

[23]  Liwu Fu,et al.  Targeting calcium signaling in cancer therapy , 2016, Acta pharmaceutica Sinica. B.

[24]  B. Thapa,et al.  Calretinin but not caveolin-1 correlates with tumour histology and survival in malignant mesothelioma. , 2016, Pathology.

[25]  Tuan Zea Tan,et al.  A COL11A1-correlated pan-cancer gene signature of activated fibroblasts for the prioritization of therapeutic targets. , 2016, Cancer letters.

[26]  S. Granjeaud,et al.  Cancer-associated fibroblast-derived annexin A6+ extracellular vesicles support pancreatic cancer aggressiveness. , 2016, The Journal of clinical investigation.

[27]  Ruedi Aebersold,et al.  Mass-spectrometric exploration of proteome structure and function , 2016, Nature.

[28]  A. Schetter,et al.  A Novel MIF Signaling Pathway Drives the Malignant Character of Pancreatic Cancer by Targeting NR3C2. , 2016, Cancer research.

[29]  D. Weaver,et al.  Targeting Focal Adhesion Kinase Renders Pancreatic Cancers Responsive to Checkpoint Immunotherapy , 2016, Nature Medicine.

[30]  Christine A Iacobuzio-Donahue,et al.  Genotype tunes pancreatic ductal adenocarcinoma tissue tension to induce matricellular-fibrosis and tumor progression , 2016, Nature Medicine.

[31]  P. Zhang,et al.  Meta-analysis of transcriptome data identifies a novel 5-gene pancreatic adenocarcinoma classifier , 2016, Oncotarget.

[32]  R. Gibbs,et al.  Genomic analyses identify molecular subtypes of pancreatic cancer , 2016, Nature.

[33]  José A. Dianes,et al.  2016 update of the PRIDE database and its related tools , 2015, Nucleic Acids Res..

[34]  Y. Ishihama,et al.  Feasibility of label-free phosphoproteomics and application to base-line signaling of colorectal cancer cell lines. , 2015, Journal of proteomics.

[35]  Jen Jen Yeh,et al.  Virtual microdissection identifies distinct tumor- and stroma-specific subtypes of pancreatic ductal adenocarcinoma , 2015, Nature Genetics.

[36]  S. Hanash,et al.  Carboxylesterase 2 as a Determinant of Response to Irinotecan and Neoadjuvant FOLFIRINOX Therapy in Pancreatic Ductal Adenocarcinoma. , 2015, Journal of the National Cancer Institute.

[37]  M. J. van de Vijver,et al.  Establishment of patient-derived xenograft models and cell lines for malignancies of the upper gastrointestinal tract , 2015, Journal of Translational Medicine.

[38]  Subhajyoti De,et al.  An assessment of computational methods for estimating purity and clonality using genomic data derived from heterogeneous tumor tissue samples , 2015, Briefings Bioinform..

[39]  Matthew E. Ritchie,et al.  limma powers differential expression analyses for RNA-sequencing and microarray studies , 2015, Nucleic acids research.

[40]  P. Ferdinandy,et al.  Myostatin and IGF-I signaling in end-stage human heart failure: a qRT-PCR study , 2015, Journal of Translational Medicine.

[41]  D. Schadendorf,et al.  A randomized controlled comparison of pembrolizumab and chemotherapy in patients with ipilimumab-refractory melanoma , 2015, Journal of Translational Medicine.

[42]  Stefan Luther,et al.  Toward panoramic in situ mapping of action potential propagation in transgenic hearts to investigate initiation and therapeutic control of arrhythmias , 2014, Front. Physiol..

[43]  Jianmin Wu,et al.  Genome‐wide DNA methylation patterns in pancreatic ductal adenocarcinoma reveal epigenetic deregulation of SLIT‐ROBO, ITGA2 and MET signaling , 2014, International journal of cancer.

[44]  Stephen A. Sastra,et al.  Stromal elements act to restrain, rather than support, pancreatic ductal adenocarcinoma. , 2014, Cancer cell.

[45]  Dana M. Brantley-Sieders,et al.  Genetic and pharmacologic inhibition of EPHA2 promotes apoptosis in NSCLC. , 2014, The Journal of clinical investigation.

[46]  B. Han,et al.  TRIM29 as a Novel Biomarker in Pancreatic Adenocarcinoma , 2014, Disease markers.

[47]  W. Burns,et al.  A novel chimeric antigen receptor against prostate stem cell antigen mediates tumor destruction in a humanized mouse model of pancreatic cancer. , 2014, Human gene therapy.

[48]  T. Nakadate,et al.  Involvement of annexin A8 in the properties of pancreatic cancer , 2014, Molecular carcinogenesis.

[49]  R. Pirola,et al.  Stars and stripes in pancreatic cancer: role of stellate cells and stroma in cancer progression , 2014, Front. Physiol..

[50]  R. Tavares,et al.  Calretinin expression in high-grade invasive ductal carcinoma of the breast is associated with basal-like subtype and unfavorable prognosis. , 2013, Human pathology.

[51]  J. Mehta,et al.  Hevin Plays a Pivotal Role in Corneal Wound Healing , 2013, PloS one.

[52]  B. Schwaller,et al.  Calretinin is essential for mesothelioma cell growth/survival in vitro: A potential new target for malignant mesothelioma therapy? , 2013, International journal of cancer.

[53]  David Goldstein,et al.  Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. , 2013, The New England journal of medicine.

[54]  J. R. de los Toyos,et al.  Overexpression of COL11A1 by Cancer-Associated Fibroblasts: Clinical Relevance of a Stromal Marker in Pancreatic Cancer , 2013, PloS one.

[55]  G. Getz,et al.  Inferring tumour purity and stromal and immune cell admixture from expression data , 2013, Nature Communications.

[56]  Sander R Piersma,et al.  Whole gel processing procedure for GeLC-MS/MS based proteomics , 2013, Proteome Science.

[57]  E. Giovannetti,et al.  The good, the bad and the ugly: a tale of miR-101, miR-21 and miR-155 in pancreatic intraductal papillary mucinous neoplasms. , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

[58]  T. Rikiyama,et al.  Nm23/nucleoside diphosphate kinase-A as a potent prognostic marker in invasive pancreatic ductal carcinoma identified by proteomic analysis of laser micro-dissected formalin-fixed paraffin-embedded tissue , 2012, Clinical Proteomics.

[59]  John W M Martens,et al.  Optimized nLC-MS workflow for laser capture microdissected breast cancer tissue. , 2012, Journal of proteomics.

[60]  Michael Schroeder,et al.  Google Goes Cancer: Improving Outcome Prediction for Cancer Patients by Network-Based Ranking of Marker Genes , 2012, PLoS Comput. Biol..

[61]  E. Giovannetti,et al.  Critical role of laser microdissection for genetic, epigenetic and proteomic analyses in pancreatic cancer , 2011, Expert review of molecular diagnostics.

[62]  Pierre Michel,et al.  FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. , 2011, The New England journal of medicine.

[63]  P. Spellman,et al.  Subtypes of Pancreatic Ductal Adenocarcinoma and Their Differing Responses to Therapy , 2011, Nature Medicine.

[64]  S. Sen,et al.  A Migration Signature and Plasma Biomarker Panel for Pancreatic Adenocarcinoma , 2010, Cancer Prevention Research.

[65]  Wolfgang Viechtbauer,et al.  Conducting Meta-Analyses in R with the metafor Package , 2010 .

[66]  Kristian Pietras,et al.  Hallmarks of cancer: interactions with the tumor stroma. , 2010, Experimental cell research.

[67]  Peter J. Woolf,et al.  GAGE: generally applicable gene set enrichment for pathway analysis , 2009, BMC Bioinformatics.

[68]  Feng Luo,et al.  Core and periphery structures in protein interaction networks , 2009, BMC Bioinformatics.

[69]  Jian Huang,et al.  Regularized gene selection in cancer microarray meta-analysis , 2009, BMC Bioinformatics.

[70]  M. Mann,et al.  MaxQuant enables high peptide identification rates, individualized p.p.b.-range mass accuracies and proteome-wide protein quantification , 2008, Nature Biotechnology.

[71]  Lixin Sun,et al.  Derlin-1 Is Overexpressed on the Tumor Cell Surface and Enables Antibody-Mediated Tumor Targeting Therapy , 2008, Clinical Cancer Research.

[72]  P. Murawa,et al.  Erlotinib Plus Gemcitabine Compared With Gemcitabine Alone in Patients With Advanced Pancreatic Cancer: A Phase III Trial of the National Cancer Institute of Canada Clinical Trials Group , 2023, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[73]  Pablo Tamayo,et al.  Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[74]  S. Ashley,et al.  EphA2: a determinant of malignant cellular behavior and a potential therapeutic target in pancreatic adenocarcinoma , 2004, Oncogene.

[75]  M. Tsao,et al.  Long-term culture and immortalization of epithelial cells from normal adult human pancreatic ducts transfected by the E6E7 gene of human papilloma virus 16. , 1996, The American journal of pathology.

[76]  N. Lemoine,et al.  Tissue factor expression correlates with histological grade in human pancreatic cancer , 1995, The British journal of surgery.

[77]  S Hanash,et al.  Surfaceome profiling enables isolation of cancer-specific exosomal cargo in liquid biopsies from pancreatic cancer patients , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.